CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.
Sci Transl Med., May;4(134):134ra62 (2012)
How genetic variant libraries effectively extend gene testing patents: implications for intellectual property and good clinical care.
J. Clin. Oncol., Aug;30(24):2943-5 (2012)
Cancer treatment according to BRCA1 and BRCA2 mutations.
Nat Rev Clin Oncol., Aug;9(9):520-8 (2012)
Therapeutic approaches for women predisposed to breast cancer.
Annu. Rev. Med., 62:295-306 (2011)
Breast cancer in young women.
Breast Cancer Res., 12(5):212 (2010)
Clinical management of hereditary breast cancer syndromes.
J Mammary Gland Biol Neoplasia., Apr;16(1):17-25 (2011)
Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
LDI Issue Brief., 16(2):1-4 (2010)
Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer.
Cancer Immunol. Immunother., Apr;59(4):599-607 (2010)
Breast cancer gene variants: separating the harmful from the harmless.
J. Clin. Invest., Oct;119(10):2895-7 (2009)
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
Breast Cancer Res. Treat., Nov;124(1):195-203 (2010)
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
Clin. Cancer Res., Jul;16(13):3485-94 (2010)
Breast cancer predisposition syndromes.
Hematol. Oncol. Clin. North Am., Oct;24(5):799-814 (2010)
The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.
Cancer Res., Sep;68(17):7006-14 (2008)
Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res., 10(4):108 (2008)
Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Fam. Cancer., 8(1):23-8 (2009)
Clinical implications of low-penetrance breast cancer susceptibility alleles.
Curr Oncol Rep., Jan;11(1):8-14 (2009)
Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT.
Cancer Biol. Ther., Dec;6(12):1991-6 (2007)
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.
Breast J., 15(1):4-16 (2009)
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
J. Natl. Cancer Inst., Jan;101(2):80-7 (2009)
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
Cancer Res., Jul;69(14):5801-10 (2009)